GlaxoSmithKline oral care sales
This article was originally published in The Rose Sheet
Executive Summary
Revenues for oral care products rose 71% to $1.59 bil. in 2001 including the Block Drug business, acquired in January 2001. Excluding Block brands, sales for oral care products, led by Aquafresh, were up 3% to $956 mil. "The profits made by Block Drug before we acquired it were doubled" during the year, GSK CEO Jean-Peirre Garnier reported at a year-end analyst presentation Feb. 14. "We were able to do some clever cost-cutting, to expand their franchises, their great brands like Sensodyne, in countries where they were not particularly strong, and we think that is going also to help drive the sales line and the profit line" for the company's consumer business...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.